Trial Profile
A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 and Day 5 fresh embryo transfer cycles
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Nolasiban (Primary)
- Indications Female infertility
- Focus Registrational; Therapeutic Use
- Acronyms IMPLANT2
- Sponsors ObsEva
- 04 Aug 2021 Results published in an ObsEva Media Release.
- 04 Aug 2021 According to an ObsEva media release, results of meta-analysis of three studies (IMPLANT, IMPLANT2 & IMPLANT 4) assessing pregnancy rate in the nolasiban 900 mg vs placebo groups, published in the Journal of Human Reproduction.
- 21 Oct 2020 Results of meta-analysis of three studies (IMPLANT, IMPLANT2 & IMPLANT 4) assessing pregnancy rate in the nolasiban 900 mg vs placebo groups, presented at the American Society for Reproductive Medicine Scientific Congress 2020.